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Abstract
Background: Since a genetic disposition for depression is probable, there ought to be biochemical
changes. Increased peptide levels with relevant bioactivities have been found in urine in a previous
investigation, which may be such changes.
Methods: Urine from patients with severe depression according to ICD 10 have been run on
reversed phase High Performance Liquid Chromatography, and off line mass spectrometry was
performed on some of these peptides.
Results:  We find overlapping patterns of peptide peaks in severe depression, but with
considerable individuality. Mass spectrometry shows that some of these peptides are probably of
dietary origin, because their sequences are found only in certain dietary proteins. Opioids from
casein and gliadin are typical examples.
Conclusion: Our data show that the disposition must be polygenetic because some peptide peaks
with the same bioactivity are of different length in different patients, but with the same diagnosis.
However, some of the peaks are common Peptide increase in urine is found when break down is
deficient, and the data presented agree with reports on peptidase deficiencies in depression.
Antidepressant drugs decrease the peptide level after about 3 weeks.
Background
Considerable evidence indicates a genetic disposition for
severe depressions [1-4], which of necessity entails chem-
ical changes. The disease takes time to develop, which
probably points to unknown substances increasing and,
or decreasing until they reach a critical level. We have pre-
viously found increased low molecular weight peptides
(fragments of proteins) in urine from patients with
depression [5,6] diagnosed according to The Diagnostic
Manual of Mental Disorder, 3rd edition (DSMIII). A pep-
tide fraction was found that stimulated the uptake of sero-
tonin (5-HT) into platelets [7] Compounds with opioid
activity were also found. On account of the confusing and
varied patterns and levels of compounds found in urinary
profiles from subjects with depression, we wanted to
study a severely ill group to try to tease out what is typical.
Some of the peptides have been purified guided by serot-
onin uptake stimulation in platelets [7], opioid receptor
binding and/or antibody binding assay [8]. Other pep-
tides have been purified using their mass-spectrometric
molecular weight as a guide.
Patients and methods
Patients were diagnosed mainly by our psychiatrist (TH)
according to ICD 10. However, single cases were obtained
from various psychiatrists over many years. All 36 patients
were severely depressed, needing hospital care and were
without medication for at least five weeks. Twentyfour
Published: 14 September 2007
Behavioral and Brain Functions 2007, 3:47 doi:10.1186/1744-9081-3-47
Received: 27 October 2005
Accepted: 14 September 2007
This article is available from: http://www.behavioralandbrainfunctions.com/content/3/1/47
© 2007 Liu et al; licensee BioMed Central Ltd. 
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), 
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.Behavioral and Brain Functions 2007, 3:47 http://www.behavioralandbrainfunctions.com/content/3/1/47
Page 2 of 7
(page number not for citation purposes)
females and 12 males were included in the untreated
group with an age range of 26–58 years. Eight were
depressed bipolar (F31.5) and we could see no systematic
difference in pattern and level of peptides comparing
depressed with ICD-10 diagnosis F 32.3, (n = 13) and F
33.3 (n = 15) compared to F 31.5 (n = 8). Therefore all
depressions were treated as one group. The treated group
used tricyclic anti-depressant or selective serotonin
reuptake inhibitors. No difference was found between the
two medicated groups and they were therefore treated as
one group made up of 18 patients. Twelve females and 6
males with an age range of 23–60. Three males and 8
females were part of the original untreated group, and
reanalyzed after 5 weeks of anti-depressive treatment
(Table 1). Normal controls were obtained from the hospi-
tal staff, nurses, teachers and the Kings Guard regiment.
Of these controls none had seen a psychiatrist or psychol-
ogist or had suicidal ideas. Their age ranged from 16 to 65
and 118 were female and 99 males. We here report on the
urinary state in severe depression only. We have previ-
ously found a lack of peptides during mania/hypomania
[6].
Urine collection
For pattern analysis the first morning urine and for purifi-
cation purposes a complete 24 diuresis were collected
under supervision (The pattern and levels of compounds
were not statistically different comparing morning urine
to a 24 h diuresis) and frozen. After thawing, the pH was
measured and creatinine determined by the Clinical
Chemical Laboratory at Rikshospitalet using standard
technique. 0.5 ml urine was pipetted into Costar Spin-x
centrifuge filter units (205 Broadway, Cambridge Ma
02139, USA) with cellulose acetate filters of pore radius
0.22 µm and centrifuged at 4000 × g for 30 minutes at
20°C. Filtrate equivalent to 250 nano-moles of creatinine
was applied to the column. The column was a C-18
reverse phase column(Vydac C-18 column 0.5 × 25 cm,
Hesperia, Ca, USA) detailed elsewhere [9]. Standards
obtained from Calbiochem-Novabiochem, AG, Läufelin-
gen, CH-4448, Switzerland and Bachem (Bubendorf,
Switzerland) were analyzed after every 11 HPLC runs and
spiked urine runs were used when needed.
Gel filtration
Was performed on Sephadex G-25 columns to separate
high and low molecular weight compounds (Dimensions
1.6 × 90 cm run in 0.5 M acetic acid at 0.4 ml/min, appli-
cation volume 10 ml). After rota-vapor concentration 10
ml of filtered low MW fractions were run on P2 gels (1.6
× 90 cm) again in 0.5 M acetic acid. Off line alkaline
hydrolysis and neutralization of 5% aliquots and ninhy-
drin colouring in an acetate/cyanide buffer was read at
570 nm [8]. This has the advantage that tryptophan is not
destroyed by the hydrolysis and the amino acids have
equimolar absorption at this wavelength with this
method.
Mass spectrometry
Material obtained from the chromatography peaks was
analyzed on the PeSciex API 2000 LC/MS/MS system. The
peptides were dissolved in 50% by volume methanol/
water/0.01 M formic acid, filtered through Millex GS 0.22
µm filter unit from Millipore, and run in the positive ion
mode, and if possible also in the negative ion mode. A
blank was run prior to each test sample and because of the
high ability for peptides to bind to surfaces, prolonged
washing was required. Fragmentation patterns (MS/MS)
were compared to that of commercially available standard
peptides. The theoretical mass was calculated from tables
provided by Micromass UK Ltd, Manchester, UK and com-
pared to the found mass. We chose the average mass dif-
ferent from the mono-isotopic mass. This is the isotopic
mix usually found in nature today. To calculate the MW
the MW for each amino acid with one Hydrogen removed
and an OH group removed is added with addition of one
H for the N terminal amino acid and either water (17 dal-
tons) or 16 daltons for C terminal amide and +1 for the
positive charge N terminally of NH3 +. The reason for this
is that one molecule of water is lost for each peptide bond
formed.
Platelet preparation
Platelets were obtained from healthy post-puberty males
and were prepared as described [7]. Because the Fura-2
calcium marker leaks out of platelets that were cooled to
4°C during the preparation, the platelets were prepared
with glucose and pyruvate to ensure viability at 20°C [7].
Table 1: Severe Depression and the level of peptides.
Disorder Depr. 
Female
Depr. 
Male
Treated Control 
Female
Control 
Male
Average 812 766 335 252 221
SD 263 257 106 101 69
N 2 41 31 8 1 1 8 9 9
95% CI
Lower 
value
701 611 254 234 208
Higher 
value
923 921 417 271 235
t: 20.8 17.7
df: 340 140
p < 0.001 0.001
Area is measured in µmeter2 under the 215 nanometer curve 
integrated by computer. 215 nano-meters was taken to represent 
the peptide bonds mostly. To control for drugs the UV 280 nm 
absorption is measured simultaneously. It was difficult to get 
untreated patients hence the small numbers. P values were obtained 
using students t test is for females against controls and males against 
controls. All treated patients (male and female) were on tricyclic 
anti-depressants or cipramil.Behavioral and Brain Functions 2007, 3:47 http://www.behavioralandbrainfunctions.com/content/3/1/47
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For buffers and details see Pedersen et al 1999 [7]. Platelet
count was adjusted to 1.5 × 108 platelets per ml with
buffer.
Serotonin uptake into platelets
The re-suspended platelets were divided in aliquots of 450
µl stored at 4°C [7] and when used pre-incubated for 10
min at 37°C. For some unknown reason far more stable
uptake data were obtained if stored at 4 degrees [10]. The
aliquots were incubated with various concentrations of
the peptides in 25 µl buffer and for 4 min, and after 2 min
(14C)-5-HT (Amersham Life Science, UK) in 25 µl was
added to a final concentration of 1 µM and 41530 cpm
and uptake run for 2 min, the time when the uptake is still
linear. For details see Pedersen et al 1999 [7].
This factor and other peptides were purified as described
[7,8]. Briefly: a complete 24 h diuresis was reduced by
evaporation under reduced pressure (rota-vapor) to 10 ml
and applied to gel filtration on G-25 to separate protein
from low MW compounds. Peptides were separated from
amino acids and salts as described [11] and subsequently
the low MW fractions were filtered on P2 gels in 0.5 M ace-
tic acid. Composition of purified peptides was found by
hydrolysis in 6 M HCl (Merck) with traces of phenol to
protect tyrosine and phenylalanine, in closed glass
ampoules at 110°C. for 14 hours. HCL was removed over
KOH and P2O5 in vacuum. Amino acid analysis was per-
formed on the Alpha plus amino acid analyzer (Pharma-
cia, Uppsala, Sweden) using the ninhydrin technique as
ordained for the apparatus. The average from three analy-
ses is given under each peptide. Peptide separation form
amino acids is as described [11].
Results
Figure 1 shows a typical HPLC peptidogram from the
urine of an asymptomatic control and 1b below is from a
psychotic, depressive female age 32(F 33.3). The urinary
peptide pattern of two depressed persons (Figures 2a and
2b) both males with ICD 10 diagnosis F 33.3 or serious
recurring depressive episode with psychotic symptoms.
They both had pronounced symptoms like depressed
mood, feeling of guilt, loss of interest and work ability,
psychic anxiety and depersonalization. Considerable dif-
ferences were found in patients with the same sex, age, dis-
order and degree of depression. For statistical analysis of
the peaks eluting after hippuric acid and prior to thymol,
the peaks were expressed as area under the 215 nano-
meter curve (Table 1). The peptide nature of the com-
pounds has been shown by hydrolysis and re-chromatog-
raphy of the released amino acids on an amino acid
analyzer [8] In Table 1 the quantitative results of
untreated, treated and controls is presented. The differ-
ence is statistically very significant (Table 1), where male
and female controls and treated patients had a significant
lower level of peptide excretion (p < 0.05)
After gel filtration of urines the most commonly seen pat-
tern (n = 15) of three patients with diagnosis F 33.3 is pre-
sented in Figure 3 The gel-filtration constants and the
frequency of their occurrence in depression are shown in
Table 2. The table again illustrates the chemical heteroge-
neity of these disorders. We could not classify depressions
according to profiles.
The top trace is a typical 215 nm normal elution pattern  from a control on c-18 reverse phase column Figure 1
The top trace is a typical 215 nm normal elution pattern 
from a control on c-18 reverse phase column. (Vydac C-18 
protein and peptide column, Vydac, Hesperia, Ca 250 × 4.5 
mm) at 30 degrees C [11]. First morning urine equivalent to 
250 nano-moles of creatinine was applied. The peaks after 
hippuric acid were integrated by the HPLC attached compu-
ter. The bottom trace is from a severely depressed female 
patient age 33 yr (Diagnosis: F: 33.3).
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Serotonin uptake into platelets
In fig 4 the uptake of serotonin into platelets is shown for
the final purification step of a tri-peptide with MW =
372.4(expected weight = 372.36) with the M+1 species
373.4 (Figure 5). The probable amino acid E = 1 and G =
1.3 and W (tryptophan) was calculated form UV absorp-
tion at 280 nm comparing to synthetic Pyroglu-
TrpGlyNH2(pE-W-GNH2)[7]. The uptake curve is typi-
cally bell shaped and is found for many peptides [12], and
the optimal dose is different from the control with p =
0.001 (n = 9), two tailed. We therefore propose that this
peptide may be responsible for serotonin removal into
platelets and synapses as found for the amidated tri-pep-
tide [7]. Peptides seen in fig 5 are discussed below, while
compounds found in different gel filtration peaks in
some, but not all patients are seen in Table 3. Spiking the
samples with standards and co-chromatography on HPLC
as well as correct amino acid composition was a prerequi-
site for inclusion in the table. Examples of mass spectrum
of the compounds found in the Kav = 0.61 and 0.66 peaks
after gel filtration, is given below. The MW is average of
three and the following peptides can all be seen in Figure
5: 2a and 2b HPLC chromatogram from two depressed and  hospitalized males with the same diagnosis (ICD 10: F33.3),  and age (35 yr) Figure 2
2a and 2b HPLC chromatogram from two depressed and 
hospitalized males with the same diagnosis (ICD 10: F33.3), 
and age (35 yr). Note the difference in pattern in spite of 
similar diagnosis, sex and age. The reproducibility of the 
points of elution running controls after each buffer renewal: 
For beta-casomorphine (bovine) 1–7: X ± SD = 62.18 ± 0.24 
ml (n = 38); 95% Confidence interval = 62.10–62.26. For the 
beta-casomorphine like peak 1–5: 50.14 ± 0.19 (n = 38) and 
95% Confidence interval = 50.08–50.20.
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Gel filtration on P 2 gels 1.6 × 90 cm in 0.5 M acetic acid of  24 h complete urine of three patients suffering from depres- sion Figure 3
Gel filtration on P 2 gels 1.6 × 90 cm in 0.5 M acetic acid of 
24 h complete urine of three patients suffering from depres-
sion. (ICD F33.3). The patients were on usual food supply 
but hospitalized. Whatman 3 MM paper filters was used to 
filter urine. Elution was monitored by measuring 5% aliquots 
by off line alkaline hydrolysis and ninhydrin colour developed 
as described [9], and with an equimolar absorption coeffi-
cient for peptides measured at 570 nm for each amino acid.
P2 gel filtration
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Table 2: Gel filtration characteristics of low MW peaks separated 
by size.
Kav Frequency
0.20 3/27
0.46 11/27
0.50 25/27
0.61 26/27
0.66 20/27
0.74 8/27
0.83 1/27
The frequency of the low MW peak maxima typical for depressions 
analyzed by gel Filtration expressed as Kav values (A gel-filtration 
constant) is shown.
Kav = Elution volume – Void volume/Total volume – Void volume. 
Depression shown here is of psychomotorically retarded psychotic 
depression. All were drug free and collected over 18 years.
The great variation in peptide chain lengths with the same bio-activity 
from one patient to the next, makes it important to measure total 
hydrolysis releasable amino acids. This also increases the sensitivity of 
the assay because splitting peptide bonds increase the amino groups 
that can be coloured with ninhydrin [8].Behavioral and Brain Functions 2007, 3:47 http://www.behavioralandbrainfunctions.com/content/3/1/47
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1 From the composite peak with Kav = 0.61 a compound
with MW+1 = 505.4 (fig 5) yielded on amino acids Y =
0.8; P = 1.9; traces of G and E = 1. Found mass+1 = 505.4
(Expected mass +1 = 505.54). This fits gliadin-morphine
1–4 deamidated or Y-P-E-P.
2 Also in the Kav = 0.66 and 0.61 peak beta-casomorphine
3–6 with amino acid composition F = 0.9; P = 2; G = 1.4.
(Glycine always appear higher than expected even in
standard synthetic compounds). Found MW +1 =
417.5(Expected = 417.4), which thus agrees with F-P-G-P.
(Figure 5, the MW came out as 417.6) or casomorphine 3–
6. 3 MW+1 = 357.2 from the Kav = 0.66 peak likewise fits
Lactoferrin 310–313 or SP-P-G or theoretical MW+1 =
357.37 and hydrolysis gave P(2), S(0,9) and G (1.4).
4 With a MW+1 of MW+1 = 489.3 (Expected = 489.5)
probably from kappa-casein has a reasonable structure of
L-P-Y-P (casein kappa 56–59). Amino acid composition
was quite varying but V = 1, Y = 0.6, P = 2. (Glycine was
sometimes found but varied from 0 to 1.)
We also obtained a peak that eluted with substance P (co-
chromatography after spiking). However, it clogged (for
unknown reason) the capillary electrode in the mass spec-
trometer, so we were unable to obtain its mass and frag-
mentation pattern.
Discussion
We have found substantial increase in peptide excretion in
severe depression. To our surprise the level was found to
be decreased in treated patients. Increase in peptides espe-
cially in urine is usually due to peptidase deficiency or
inhibition [13,14]. The presented data indicate that
severely depressed patients show hyper-peptiduria as
would be expected if peptidase defects were present. Pepti-
dase deficiencies have been found in depression and mel-
Mass spectrometry of the peak from gel filtration with Kav =  0.61 characteristically partially overlapping with the peak  with Kav = 0.66 Figure 5
Mass spectrometry of the peak from gel filtration with Kav = 
0.61 characteristically partially overlapping with the peak 
with Kav = 0.66. The serotonin uptake stimulator is seen 
with mass +1 = 373.4 and a peptide with unknown function 
and mass +1 of 505.4(Y-P-E-P) which fits deamidated gliadi-
nomoprhine tetrapeptide. Also casomorphine 3–6 with mass 
+1 = 417.6 is seen (F-P-G-P). A peptide with MW+1 = 489.3 
(Expected = 489.5) that may be derived from kappa-casein 
has a probable structure of L-P-Y-P (casein κ 56–59). Several 
other peptides will be published separately when elucidated. 
The figure illustrates the heterogeneity of the gel filtration 
peaks and the amount of work needed to characterize the 
many eluted compounds.
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Table 3: Probable structure of some mass spectrometric peaks 
not shown in fig 5.
Kav of 
peak
Mass 
Found
Mass 
Expected
Structure HPLC Co-
chromatography with
0.61 579.6 579.6 Y-P-F-P-
G-NH2
beta-casomorphineb 
1–5 amide
0.66 522.3 522.3 Y-P-F-P beta-casomorphineb 
1–4
0.50 888.05 888.05 Y-P-F-P-
G-P-I-P
beta-casomorphineb 
1–8*
0.50 790.9 790.9 Y-P-F-P-
G-P-I
beta-casomorphineb 
1–7
b stands for bovine. * Imuno assay for casomorphine 1–8 with 
antibodies provided by Professor Dr Teschemacher, Giessen, 
Germany in 4 patients with this HPLC peak came to 120 fentomoles 
± 30 (n = 4) while control values from the same peak area in 4 normal 
controls came to 15 ± 6 (n = 4).
Serotonin uptake stimulation of the pure peptide Figure 4
Serotonin uptake stimulation of the pure peptide. Concen-
tration of peptide along the abcissa. Platelets were prepared 
as outlined in methods. -14 is 10 to the power of -14 M(10-14 
M). The typical hormetic dose response curve is shown.
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ancholic states [15-19]. Because the level and pattern of
peptides differ, and differing chain lengths of peptides
with the same activities are found, this points to a hetero-
geneity of genetics. Different families may have a different
sets of dysfunctional enzymes probably peptidases or
peptidase binding proteins. This may explain the diffi-
culty of pinpointing a specific gene as the genetic disposi-
tion in depression. We suggest that we have depression
causing genes which may cause formation of different but
overlapping peptidases or peptidase regulating proteins,
and that the mediators of depression may be peptides reg-
ulating the uptake and release of different transmitters.
Since antidepressant medication reduced the level of pep-
tides (table 1) this could be due to peptidase induction as
has been shown for neuroleptic medication. It remains to
be seen if peptide level correlates with the degree of
depression. The presence of opioids may explain the psy-
chotic features of our patients because opioids have been
shown to cause increased dopamine in the synaptic cleft
by inhibiting reuptake [20] An exogenous supply of pep-
tides may also explain the often seen and peculiar fluctu-
ating course of the disorder with morning worsening and
afternoon a relative high or agitation. Increased reuptake
of serotonin into platelets may have relevance to the
reported changes in serotonin transport into platelets in
depression [21,22]. Both the tri-cyclic antidepressants and
selective serotonin re-uptake inhibitors have the opposite
effect on serotonin uptake. We have previously found the
tri-peptide but amidated, in autistic patients' urine and
this tri-peptide stimulated the serotonin transporter medi-
ated uptake of serotonin in hamster ovarial cells trans-
fected with the human serotonin transporter gene [23].
That tri-peptide doubled the serotonin content of platelets
when injected into pups subcutaneously [24]. 5 HT 2a
receptors are increased in brain tissue and platelets in
depression [25] which would agree with decreased levels
in the synaptic cleft due to stimulated uptake. Also the
decreased 5HIAA (5-hydroxy indole-acetic acid) in sui-
cidal patients fit an increased uptake [26]. The tri-peptide
sequence has only been found in reelin, which is a matrix
proteinase [27]. That food derived peptides are taken up
has been demonstrated [28,29] and is increased by pepti-
dase defects [30]. Depression has been found in cases of
coeliac disease [31,32] indicating that such a mechanism
is not unreasonable. Considerable differences in rates in
different cultures may also thus be explainable. Other
groups have found increases in some peptides in depres-
sion. Thus TRH (pE-H-P-NH2) has been found increased
in CSF [33,34]; beta-endorphin [35] and an unspecified
opioid fraction 1 measured by receptor binding [36,37].
Substance P was also found increased in CSF [38], and
delta sleep factor increased in plasma [39,40]. Also
plasma arginine vasopressin increase in depression was
inversely related to daytime motor activity [41]. Further-
more post partum psychosis may be mediated by different
human caso-morphines [42] and shows depressive traits.
Since peptides in general are excellent peptidase inhibi-
tors [43] and peptides also have strong tendencies to form
complexes [44,45] and bind to other molecules and mem-
branes [46,47], a rather complex situation with varied
results can be envisioned. Bell shaped dose responses are
common to many peptides and add to this complicated
picture [12]. The nature of some of these peptides is
shared with schizophrenia and may constitute the com-
mon features of these disorders [48]. Possibly relevant to
a gut-brain axis in depression is epidemiological data
showing very high frequency of depression in irritable
bowel syndrome [49-51]. Future work is needed to eluci-
date if there is a correlation of peptide increase and degree
of depression and to look for any correlations between
individual peptide peaks and specific symptoms of this
disorder.
Conclusion
In severe cases of hospitalized patients with depression,
we find peptide increase in urine. After treatment the level
is decreased. Some of these peptides affect serotonin
uptake and others show exorphine like characteristics.
Our study is based on a small number of patients due to
problems of getting untreated ones. We do not know how
general or specific these findings are to the depression
spectrum. However, our data are compatible with
reported decreased peptidase levels found by others in
depression. If correct the profound heterogeneity casts
doubt on most double blind treatment trials in depres-
sion.
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